External Validation of the DAPT Score in a Nationwide Population.

[1]  P. Kolh,et al.  [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] , 2018, Kardiologia polska.

[2]  Takeshi Kimura,et al.  Validating Utility of Dual Antiplatelet Therapy Score in a Large Pooled Cohort From 3 Japanese Percutaneous Coronary Intervention Studies , 2017, Circulation.

[3]  S. Windecker,et al.  Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention , 2017, Annals of Internal Medicine.

[4]  Spiros C. Denaxas,et al.  Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors , 2017, European heart journal.

[5]  C. Held,et al.  Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial , 2016, European heart journal.

[6]  Laura Mauri,et al.  2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Journal of the American College of Cardiology.

[7]  L. Friberg,et al.  Usefulness of Health Registers for detection of bleeding events in outcome studies , 2016, Thrombosis and Haemostasis.

[8]  J. Spertus,et al.  Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. , 2016, JAMA.

[9]  O. Angerås,et al.  Treatment pattern of contemporary dual antiplatelet therapies after acute coronary syndrome: a Swedish nationwide population-based cohort study , 2015, Scandinavian cardiovascular journal : SCJ.

[10]  L. Mauri,et al.  Balancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents. , 2015, The American journal of cardiology.

[11]  Marc P. Bonaca,et al.  Long-term use of ticagrelor in patients with prior myocardial infarction. , 2015, The New England journal of medicine.

[12]  B. van Calster,et al.  Calibration of Risk Prediction Models , 2015, Medical decision making : an international journal of the Society for Medical Decision Making.

[13]  Braunwald,et al.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. , 2014, The New England journal of medicine.

[14]  Ewout W. Steyerberg,et al.  F1000Prime recommendation of Calibration of risk prediction models: impact on decision-analytic performance. , 2014 .

[15]  P. Royston,et al.  External validation of a Cox prognostic model: principles and methods , 2013, BMC Medical Research Methodology.

[16]  D. Holmes,et al.  Drug-eluting coronary-artery stents. , 2013, The New England journal of medicine.

[17]  P. Serruys,et al.  Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial , 2012, The Lancet.

[18]  J. Ludvigsson,et al.  External review and validation of the Swedish national inpatient register , 2011, BMC public health.

[19]  L. Wallentin,et al.  Abstract 1428: Statin Use After Myocardial Iinfarction Improves Survival in Nearly All With Renal Dysfunction: Data From the Swedish Web-system for Enhancement and Development of Evidence-based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) , 2009 .

[20]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[21]  J. Ware,et al.  Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. , 2009, European heart journal.

[22]  S. Yusuf,et al.  Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. , 2009, American heart journal.

[23]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[24]  Johan Lindbäck,et al.  Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. , 2007, The New England journal of medicine.

[25]  P. Kolh,et al.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[26]  M. Fischer,et al.  Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents , 2017, Thrombosis and Haemostasis.

[27]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.